Latest Breaking News On - Sarcoma oncology center - Page 2 : comparemela.com

Salarius Pharmaceuticals, Inc. (SLRX) Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Shasqi Advances SQ3370 to Phase 2 in Solid Tumors

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

HOUSTON, Aug. 04, 2022 Salarius Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, announces the. | August 4, 2022

Tyme Technologies : Annual Report (Form 10-K)

Tyme-10k 20220331.htm Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 . | May 25, 2022

Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors

PRINCETON, NJ / ACCESSWIRE / April 13, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that dosing has